Skip to main content

Advertisement

SpringerLink
Log in

Is biomarker research advancing in the era of personalized medicine for head and neck cancer?

  • Review Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Recent progress in molecular biology and translational research has initiated an era of personalized medicine in head and neck clinical oncology. The genetic information defined by biomarker analysis in tumors and individuals is indispensable for the administration of molecular targeting agents. The epidermal growth factor receptor (EGFR) signaling pathway is an important therapeutic target in head and neck squamous cell carcinoma (HNSCC). The use of an anti-EGFR monoclonal antibody (mAb), cetuximab (Cmab), has been approved for the treatment of patients with head and neck cancer. Although KRAS mutation has been established as a potential biomarker for predicting the efficacy of anti-EGFR mAb in colorectal cancer, little is known about predictive markers for Cmab in head and neck cancer. Optimal predictive and prognostic markers as well as safety markers are required to promote the appropriate clinical use of Cmab and to determine malignant phenotypes in head and neck cancer. This article first reviews the role of EGFR signaling in HNSCC. The article then focuses on Ras/Raf/Mek/Erk and PTEN/PI3K/Akt signaling pathways as predictive markers for Cmab. Subsequently, the molecular basis and clinical outcome of human papillomavirus (HPV)-positive cancer is highlighted, and the potential role of anti-EGFR target therapy for HPV-positive HNSCC is discussed. Finally, the possible mechanism for resistance to anti-EGFR target therapy is reviewed, and I discuss approaches to overcome the resistance with reference to an ongoing clinical trial.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89–95

    Article  Google Scholar 

  2. Egloff AM, Grandis J (2006) Epidermal growth factor receptor-targeted molecular therapeutics for head and neck squamous cell carcinoma. Expert Opin Ther Targets 10:639–647

    Article  PubMed  CAS  Google Scholar 

  3. Chung CH, Ely K, McGavran L (2006) Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 24:4170–4176

    Article  PubMed  CAS  Google Scholar 

  4. Ang KK, Berkey BA, Tu X (2002) Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62:7350–7356

    PubMed  CAS  Google Scholar 

  5. Thomas SM, Grandis JR (2004) Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat Rev 30:255–268

    Article  PubMed  CAS  Google Scholar 

  6. Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578

    Article  PubMed  CAS  Google Scholar 

  7. Vermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116–1127

    Article  PubMed  CAS  Google Scholar 

  8. Van Cutsem E, Tejpar S, Vanbeckevoort D et al (2012) Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. J Clin Oncol 30:2861–2868

    Article  PubMed  CAS  Google Scholar 

  9. Bonner JA, Harari PM, Giralt J et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21–28

    Article  PubMed  CAS  Google Scholar 

  10. Vermorken JB, Trigo J, Hitt R et al (2007) Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25:2171–2177

    Article  PubMed  CAS  Google Scholar 

  11. Klinghammer K, Knödler M, Schmittel A et al (2010) Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Clin Cancer Res 16:304–310

    Article  PubMed  CAS  Google Scholar 

  12. Chung KY, Shia J, Kemeny NE et al (2005) Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23:1803–1810

    Article  PubMed  CAS  Google Scholar 

  13. Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345

    Article  PubMed  CAS  Google Scholar 

  14. Wierzbicki R, Jonker DJ, Moore MJ et al (2011) A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining. Invest New Drugs 29:167–174

    Article  PubMed  CAS  Google Scholar 

  15. Smilek P, Neuwirthova J, Jarkovsky J et al (2012) Epidermal growth factor receptor (EGFR) expression and mutations in the EGFR signaling pathway in correlation with anti-EGFR therapy in head and neck squamous cell carcinomas. Neoplasma 59:508–515

    Article  PubMed  CAS  Google Scholar 

  16. Schubbert S, Shannon K, Bollag G (2007) Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7:295–308

    Article  PubMed  CAS  Google Scholar 

  17. Bos JL (1989) Ras oncogenes in human cancer: a review. Cancer Res 49:4682–4689

    PubMed  CAS  Google Scholar 

  18. Weber A, Langhanki L, Sommerer F et al (2003) Mutations of the BRAF gene in squamous cell carcinoma of the head and neck. Oncogene 30:4757–4759

    Article  CAS  Google Scholar 

  19. Bissada E, Abboud O, Abou Chacra Z et al (2013) Prevalence of K-RAS codons 12 and 13 mutations in locally advanced head and neck squamous cell carcinoma and impact on clinical outcomes. Int J Otolaryngol. doi:10.1155/2013/848021

    PubMed Central  PubMed  Google Scholar 

  20. Van Cutsem E, Köhne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417

    Article  PubMed  Google Scholar 

  21. Bokemeyer C, Bondarenko I, Makhson A et al (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663–671

    Article  PubMed  CAS  Google Scholar 

  22. Karapetis CS, Khambata-Ford S, Jonker DJ et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757–1765

    Article  PubMed  CAS  Google Scholar 

  23. Allegra CJ, Jessup JM, Somerfield MR et al (2009) American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27:2091–2096

    Article  PubMed  Google Scholar 

  24. Yokota T, Ura T, Shibata N et al (2011) BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer 104:856–862

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  25. Di Nicolantonio F, Martini M, Molinari F et al (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26:5705–5712

    Article  PubMed  CAS  Google Scholar 

  26. Yokota T (2012) Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers? Anticancer Agents Med Chem 12:163–171

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  27. Samuels Y, Velculescu VE (2004) Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 3:1221–1224

    Article  PubMed  CAS  Google Scholar 

  28. Pedrero JM, Carracedo DG, Pinto CM et al (2005) Frequent genetic and biochemical alterations of the PI3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int J Cancer 114:242–248

    Article  PubMed  CAS  Google Scholar 

  29. Bouali S, Chrétien AS, Ramacci C et al (2009) PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells. Oncol Rep 21:731–735

    PubMed  CAS  Google Scholar 

  30. Mriouah J, Boura C, Pinel S et al (2010) Cellular response to cetuximab in PTEN-silenced head and neck squamous cell carcinoma cell line. Int J Oncol 37:1555–1563

    PubMed  CAS  Google Scholar 

  31. Gillison ML, D’Souza G, Westra W et al (2008) Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 100:407–420

    Article  PubMed  Google Scholar 

  32. Gillison ML, Koch WM, Capone RB et al (2000) Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92:709–720

    Article  PubMed  CAS  Google Scholar 

  33. Herrero R, Castellsague X, Pawlita M et al (2003) Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 95:1772–1783

    Article  PubMed  Google Scholar 

  34. Smith EM, Ritchie JM, Summersgill KF et al (2004) Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. Int J Cancer 108:766–772

    Article  PubMed  CAS  Google Scholar 

  35. Strome SE, Savva A, Brissett AE et al (2002) Squamous cell carcinoma of the tonsils: a molecular analysis of HPV associations. Clin Cancer Res 8:1093–1100

    PubMed  CAS  Google Scholar 

  36. Weinberger PM, Yu Z, Haffty BG et al (2004) Prognostic significance of p16 protein levels in oropharyngeal squamous cell cancer. Clin Cancer Res 10:5684–5691

    Article  PubMed  CAS  Google Scholar 

  37. Ragin CC, Taioli E (2007) Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer 121:1813–1820

    Article  PubMed  CAS  Google Scholar 

  38. Pai SI, Westra WH (2009) Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment. Annu Rev Pathol 4:49–70

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  39. Gillison ML, Harris J, Westra W et al (2009) Survival outcomes by tumor human papillomavirus (HPV) status in stage III–IV oropharyngeal cancer (OPC) in RTOG 0129. J Clin Oncol 27:15s (suppl; abstract 6003)

    Article  Google Scholar 

  40. Fakhry C, Westra WH, Li S et al (2008) Improved survival of patients with human papillomavirus—positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100:261–269

    Article  PubMed  CAS  Google Scholar 

  41. Mellin H, Friesland S, Lewensohn R et al (2000) Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of relapse, and survival. Int J Cancer 89:300–304

    Article  PubMed  CAS  Google Scholar 

  42. Licitra L, Perrone F, Bossi P et al (2006) High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 24:5630–5636

    Article  PubMed  CAS  Google Scholar 

  43. Thomas J, Primeaux T (2012) Is p16 immunohistochemistry a more cost-effective method for identification of human papilloma virus-associated head and neck squamous cell carcinoma? Ann Diagn Pathol 16:91–99

    Article  PubMed  Google Scholar 

  44. Begum S, Cao D, Gillison M et al (2005) Tissue distribution of human papillomavirus 16 DNA integration in patients with tonsillar carcinoma. Clin Cancer Res 11:5694–5699

    Article  PubMed  CAS  Google Scholar 

  45. Kumar B, Cordell KG, Lee JS et al (2008) EGFR, p16, HPV titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 26:3128–3137

    Article  PubMed Central  PubMed  Google Scholar 

  46. Reimers N, Kasper HU, Weissenborn SJ et al (2007) Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer 120:1731–1738

    Article  PubMed  CAS  Google Scholar 

  47. Smeets SJ, Hesselink AT, Speel EJ et al (2007) A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer 121:2465–2472

    Article  PubMed  CAS  Google Scholar 

  48. Giralt J, Fortin A, Mesia R et al (2012) A phase II, randomized trial (CONCERT-1) of chemoradiotherapy (CRT) with or without panitumumab (pmab) in patients (pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (LASCCHN). J Clin Oncol 30 (suppl; abstract 5502)

  49. Vermorken JB, Stöhlmacher-Williams J, Davidenko I et al (2013) Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol 14:697–710

    Article  PubMed  CAS  Google Scholar 

  50. Stoehlmacher-Williams J, Villanueva C, Foa P et al (2012) Safety and efficacy of panitumumab (pmab) in HPV-positive (+) and HPV-negative (−) recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): analysis of the global phase III SPECTRUM trial. J Clin Oncol 30 (suppl; abstract 5504)

  51. Feldman-Moreno RA, Kemkes AC, Xiu J et al (2012) Differences in biomarker expression in HNSCC according to p53 status. J Clin Oncol 30 (suppl; abstract 5523)

  52. Lui VW, Hedberg ML, Li H et al (2013) Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov 3:761–769

    Article  PubMed  CAS  Google Scholar 

  53. Wikstrand CJ, Hale LP, Batra SK et al (1995) Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 55:3140–3148

    PubMed  CAS  Google Scholar 

  54. Huang HS, Nagane M, Klingbeil CK (1997) The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 272:2927–2935

    Article  PubMed  CAS  Google Scholar 

  55. Sok JC, Coppelli FM, Thomas SM (2006) Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 12:5064–5073

    Article  PubMed  CAS  Google Scholar 

  56. Leemans CR, Braakhuis BJ, Brakenhoff RH (2011) The molecular biology of head and neck cancer. Nat Rev Cancer 11:9–22

    Article  PubMed  CAS  Google Scholar 

  57. Chau NG, Perez-Ordonez B, Zhang K et al (2011) The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Head Neck Oncol 3:11

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  58. Yang B, Chen J, Zhang X et al (2009) Expression of epidermal growth factor receptor variant III in laryngeal carcinoma tissues. Auris Nasus Larynx 36:682–687

    Article  PubMed  Google Scholar 

  59. Ji H, Zhao X, Yuza Y et al (2006) Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci USA 103:7817–7822

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  60. Ciardiello F, Tortora G (2003) Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer 39:1348–1354

    Article  PubMed  CAS  Google Scholar 

  61. de Souza JA, Davis DW, Zhang Y et al (2012) A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 18:2336–2343

    Article  PubMed  CAS  Google Scholar 

  62. Harrington K, Berrier A, Robinson M et al (2013) Randomised phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease. Eur J Cancer 49:1609–1618

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The author declares that he has no conflict of interest.

Author information

Authors and Affiliations

  1. Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, Shizuoka, 411-8777, Japan

    Tomoya Yokota

Authors
  1. Tomoya Yokota
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tomoya Yokota.

About this article

Cite this article

Yokota, T. Is biomarker research advancing in the era of personalized medicine for head and neck cancer?. Int J Clin Oncol 19, 211–219 (2014). https://doi.org/10.1007/s10147-013-0660-4

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-013-0660-4

Keywords

Search

Navigation